Illumina (XSWX:ILMN) Total Equity: CHF2,107 Mil (As of Mar. 2026)


XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF143.95
GF Value CHF105.51
! 7 Warning Signs
View Full Analysis

What is Illumina Total Equity?

Illumina XSWX:ILMN -0.79% 76 Total Equity is CHF2,107 Mil as of Mar. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review.

Illumina's total equity for the quarter that ended in Mar. 2026 was CHF2,107 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Illumina Total Equity Historical Data

* Premium members only.

The historical data trend for Illumina's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Total Equity Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,891.54 6,147.63 4,968.28 2,115.77 2,169.96

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,092.37 1,836.21 1,895.51 2,169.96 2,106.82
XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Illumina's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5294.604-3124.645
=2,170

Illumina's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=5163.901-3057.086
=2,107

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF2,107 Mil mean?
Illumina (XSWX:ILMN) has a Total Equity of CHF2,107 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Illumina and its competitors.
Is Illumina's Total Equity too high?
Illumina's current Total Equity is CHF2,107 Mil. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Total Equity compare to MTD and DGX?
Illumina's Total Equity of CHF2,107 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Illumina and its competitors. Illumina's current Total Equity is CHF2,107 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Total Equity of CHF2,107 Mil. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Total Equity is CHF2,107 Mil. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Total Equity is CHF2,107 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.

Key valuation signals for XSWX:ILMN:

  • Total Equity: CHF2,107 Mil
  • GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF143.95
Price
CHF105.51
GF Value